You are here

SARS-CoV-2, PSCs, and Organoids - A Review

Coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) dominate discussions in the scientific community. While clinical trials are underway worldwide, we currently lack basic research on SARS-CoV-2 entry and the replication and identification of the best drug targets. In a new STEM CELLS Translational Medicine article, researchers led by Kazuo Takayama (Kyoto University, Japan) reviews the use of human pluripotent stem cell (PSC)-derived cells and organoids in SARS-CoV-2 research, considering their strengths and weaknesses. Overall, Deguchi et al. hope that this review will help researchers select suitable human PSC-derived cells and organoids for SARS-CoV-2 studies and accelerate drug discovery for COVID-19.